Premium
Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patients
Author(s) -
MAEJIMA Hideki,
AKI Ryouichi,
WATARAI Akira,
SHIRAI Kyoumi,
HAMADA Yuko,
KATSUOKA Kensei
Publication year - 2010
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2010.00814.x
Subject(s) - psoriatic arthritis , medicine , rheumatoid arthritis , psoriasis , antibody , arthritis , immunology , antigen , bone erosion , gastroenterology , dermatology
Anti‐cyclic citrullinated peptide antibodies (anti‐CCP) are highly considered to indicate disease severity and be predictive markers in rheumatoid arthritis (RA). RA patients who are positive for anti‐CCP tend to progress more frequently to joint deformity and functionally deteriorate more than negative patients. A study concerning the presence of anti‐CCP in Japanese patients with psoriatic arthritis (PsA) has been published. Our aim was to clarify that anti‐CCP could be a potentially useful marker in PsA patients. We herein describe a PsA patient with presence of anti‐CCP. We examined anti‐CCP in 15 patients with PsA, and compared with 18 controls who had other types of psoriasis. Three PsA patients were positive for anti‐CCP, but no controls showed positive. The anti‐CCP‐positive patients had higher counts of radiographic erosion, higher prevalence rates of polyarticular disease, use of disease‐modifying anti‐rheumatic drugs, and the human leukocyte antigen DRB1*04 shared epitope than negative patients. Our study demonstrated that anti‐CCP was potentially both predictive and a severity marker of joint involvement in PsA, the same as in RA.